DOJ Sues Regeneron Over Medicare Drug Price Reporting for Eylea

The DOJ says it has filed a complaint under the False Claims Act against Regeneron Pharmaceuticals for allegedly manipulating Medicare reimbursement rates for the company’s treatment of wet AMD, Eylea.

• The agency alleges Regeneron submitted hundreds of millions of dollars of inflated average sales price (ASP) reports to Medicare
• DOJ alleges the company “knowingly failed to include price concessions in the form of credit card processing fees that Regeneron paid to specialty drug distributors to benefit its customers”
• NOTE: Regeneron Spared for Now in $1B DOJ Case, Likely Settles Later

To contact the reporter on this story:
Cameron Baker in ...